A multimodal approach to diabetic macular edema
Introduction
Diabetic retinopathy (DR) is the most common complication of diabetes, affecting one in three diabetics (Center of Disease Control National Center of Chronic Disease Prevention & Health Promotion Division of Diabetes Translation, 2015). In 2005, 5.5 million patients were affected with diabetic retinopathy, with the expectation that it would triple by 2050 to 16 million (Saaddine et al., 2008). With the prevalence of diabetes in 2013 estimated at 24.4 million in the United States and 382 million worldwide, it comes as no surprise that diabetes continues to be the leading cause of blindness in the United States (International Diabetes Foundation, nd). Although advancements in systemic management for diabetes have made major strides, management of diabetic retinopathy has remained poor.
Diabetic retinopathy is characterized by progressive bilateral damage to retinal blood vessels. It has four stages that extend from microaneurysms (either background retinopathy or mild nonproliferative retinopathy) to extensive abnormal blood vessel growth (proliferative retinopathy). Early in the disease, patients may not experience any symptomology. However, poor management of risk factors – hyperglycemia, chronically elevated hemoglobin A1C (HbA1c), hypertension and hyperlipidemia – can cause disease progression (Yau et al., 2012). Subsequently, patients can experience blurry vision, decrease in visual acuity, metamorphopsia, or other visual complaints. If left untreated, patients become incurably blind.
Vision loss in patients affected with diabetic retinopathy commonly manifests as fluid accumulates beneath the macula, the central portion of the retina responsible for high visual acuity. This occurs in all disease stages secondarily to incompetent blood vessels causing diabetic macular edema (DME) or in end stage disease when abnormal blood vessels grow (proliferative retinopathy). As a result, targeted therapy has been directed at limiting the damaging effects of poor vasculature integrity. The main goals of treatment are to: 1) manage risk factors to minimize the effects of systemic diabetes on retinal vasculature, 2) reduce fluid accumulation, and 3) prevent the consequences of fluid disrupting the retina. As the leading cause of blindness in patients with DR is DME, we will specifically outline and discuss the evolution of multimodal management of DME in this review.
Section snippets
Evolution of treatments
Historically, the treatment of DME was focused on vision stabilization. The 1985 landmark Early Treatment of Diabetic Retinopathy Study (ETDRS) established glycemic control, blood pressure regulation, and macular laser photocoagulation as standard of care (Early Treatment of Diabetic Retinopathy Study, 1985). The intent of laser photocoagulation was to reduce leaky micro-aneurysms and inhibit extravasation of fluid into the macula, thereby preventing degradation of vision. The study
Anti-VEGF therapy
Multiple clinical trials elucidated anti-VEGF in the reversal, stabilization, and prevention of future vision loss. We briefly outline the major clinical trials in Table 1 for the following three VEGF targeting drugs: ranibizumab (Lucentis), bevacizumab (Avastin), and aflibercept (Eylea).
Side effects of anti-VEGF therapy
With anti-VEGF therapy becoming the new standard of care, evaluation of long-term side effects and adverse events is necessary. This is of increasing significance, as management of DME requires frequent anti-VEGF administration. Here, we summarize the more frequent and alarming side effects (Table 2).
Comparison of anti-VEGF therapy
In 2015, DRCR.net performed a randomized clinical trial designated Protocol T to compare the efficacy of anti-VEGF therapy. The implications of Protocol T help define whether off-label bevacizumab ($50), a less costly anti-VEGF therapy, would be equivalent to its newer, FDA approved equivalents aflibercept ($1950) or ranibizumab ($1200). In patients with vision equivalent to 20/50 or worse at baseline, aflibercept (+ 18.9 ± 11.5 letters of vision improvement from baseline) significantly improved
Corticosteroid therapy
Based upon insights into the multifactorial pathophysiology of DME and the preliminary findings in the DRCR.net Protocol I study, corticosteroids have become an alternative therapy for treating DME. In particular, the following outlined clinical trials regarding the three major corticosteroids demonstrate how corticosteroids may play a role in refractory DME, or persistent DME despite laser therapy.
Side effects of corticosteroid therapy
Intravitreal administration of corticosteroids is well tolerated with minimal systemic side effects. This is most likely due to the limited passage of corticosteroids into the systemic circulation after intravitreal injection (Degenring & Jonas, 2004). Although many side effects have been reported, we present the more common and concerning side effects (Table 2).
Combinatorial therapies
Although many of the aforementioned clinical trials establish effectiveness with monotherapy of laser, anti-VEGF, or corticosteroids, evaluation of combinatorial management has shown promise. These synergistic effects may be explained pathophysiologically with targeting multiple mechanistic pathways, promoting laser effectiveness by reducing macular thickness, reducing respiratory requirements in photocoagulated regions, or steroids modulating the function of the retinal pigment epithelium.
Evolving anti-inflammatory and anti-VEGF management strategies
The establishment of pharmacologic therapies against diabetic retinopathy has allowed further investigation in novel therapeutics that go beyond the broad scope of steroids and anti-VEGF antibodies. We will briefly highlight a few of the drugs that are currently in development.
VEGF-related therapeutics
Since the study of the three anti-VEGF antibodies (bevacizumab, ranibizumab, and aflibercept), two major drawbacks have spurred advancements in anti-VEGF related therapeutics: non-responders and burdensome monthly injections. A conceivable explanation for both limitations is that molar concentrations of anti-VEGF therapies are inadequate. In support, the inverse may explain why aflibercept, possibly at higher molar concentrations as compared to its anti-VEGF counterparts, showed improved
Reducing side effects: endophthalmitis
The most concerning side effect is endophthalmitis and significant measures have been taken to reduce the likelihood of intraocular infection. There are four main procedural tasks, as seen in DRCR.net and SCORE clinical trials, performed to prevent endophthalmitis. They are as follows: 1) pre-injection ocular irrigation with povidone-iodine (PI), 2) application of sterile lid speculum, 3) reduction in talking during injection, and 4) utilization of prophylactic antibiotics. A prospective
Conclusion
Anti-VEGF therapy and corticosteroids have provided alternative therapies in the management of DME, a previously crudely treated complication of diabetes. Identification of these modalities has, in isolation, proven to not only stabilize but also improve vision. In treatment naive patients, anti-VEGF therapy has essentially replaced laser photocoagulation as the new standard of care. However, rescue or supplemental laser therapy was routinely utilized throughout all clinical trials. In patients
Acknowledgements
1) Funding/support: none; 2) Financial disclosures: Alcon Laboratories (RPS), Genentech (RPS), Regeneron (RPS), Allergan (RPS), ThromboGenics (RPS), Shire (RPS).
References (75)
- et al.
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema
Ophthalmology
(2014) - et al.
Diabetic retinopathy
Lancet
(2010) - et al.
Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies
American Journal of Ophthalmology
(2009) - et al.
Serum levels of triamcinolone acetonide after intravitreal injection
American Journal of Ophthalmology
(2004) - et al.
One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema
Ophthalmology
(2012) - et al.
Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema
Ophthalmology
(2003) - et al.
Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial
Ophthalmology
(2006) - et al.
Clinically significant macular edema and survival in type 1 and type 2 diabetes
American Journal of Ophthalmology
(2008) - et al.
Ophthalmic antibiotics and antimicrobial resistance
(2011) - et al.
Intravitreal aflibercept for diabetic macular edema
Ophthalmology
(2014)
Intravitreal triamcinolone for refractory diabetic macular edema
Ophthalmology
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results
Ophthalmology
The RESTORE study: Ranibizumab monotherapy or combined with laser versus monotherapy for diabetic macular edema
Ophthalmology
A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections
Ophthalmology
Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE
Ophthalmology
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study
Ophthalmology
Fluocinolone acetonide intravitreal implant for diabetic macular edema: A 3-year multicenter, randomized, controlled clinical trial
Ophthalmology
Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema
Ophthalmology
Prophylaxis of endophthalmitis with topical povidone-iodine
Ophthalmology
The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection
Ophthalmology
Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema
Ophthalmology
Immunological mechanisms in the pathogenesis of diabetic retinopathy
Seminars in Immunopathology
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
The New England Journal of Medicine
Center of Disease Control National Center of Chronic Disease Prevention and Health Promotion Division of Diabetes Translation, Diabetic retinopathy
Diabetic Retinopathy Center Group
Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease
Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema
American Journal of Ophthalmology
Inhibition of oxygen-induced retinopathy in RTP801-deficient mice
Investigative Ophthalmology & Visual Science
Ranibizumab versus verteporfin for neovascular age-related macular degeneration [ANCHOR study 1-year data]
The New England Journal of Medicine
Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema
Ophthalmology
Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase I/II study
American Journal of Ophthalmology
Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections
Ophthalmology
Microvascular lesions of diabetic retinopathy: Clues toward understanding pathogenesis?
Eye (London, England)
Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema
Journal of Cellular Physiology
A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema
Ophthalmology
A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema
Ophthalmology
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
The New England Journal of Medicine
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
Ophthalmology
Cited by (11)
Identification and Prediction of Diabetic Macular Edema on Two-dimensional Fundus Images with Raphe Assessment and Deep Convolution Neural Networks
2022, Biomedical and Environmental SciencesPhytonanoparticles toward the treatment of diabetes
2022, Drug Delivery Systems for Metabolic DisordersPolymeric nanomicelles based on inulin D α-tocopherol succinate for the treatment of diabetic retinopathy
2021, Journal of Drug Delivery Science and TechnologyCitation Excerpt :After 15 years being diabetic, approximately 2% of people become blind, while about 10% develop severe visual handicap. DR is characterized by a progressive bilateral damage of retinal blood vessels, resulting in loss of vision [2]. Hyperglycaemia, hypertension, dyslipidaemia and obesity are recognized as the most clinically significant risk factors that lead to vision loss.
Study of stability and biophysical characterization of ranibizumab and aflibercept
2016, European Journal of Pharmaceutics and BiopharmaceuticsCitation Excerpt :A very recent study has brought to light a similar binding affinity of ranibizumab and aflibercept to VEGF165 [6]. The aforementioned chronic back-of-the-eye diseases require periodic, usually monthly, intravitreal (IVT) injections to maintain the therapeutic benefit of these anti-VEGF proteins [7,8]. As these injections are painful, there is usually poor patient compliance as well as increased workload for ophthalmologists who must administer these injections.
The effectiveness of laser treatment for diabetic retinopathy in patients with chronic kidney disease
2021, International Journal of BiomedicineAflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema
2019, Graefe's Archive for Clinical and Experimental Ophthalmology
Conflicts of interest:
Au: none.
Singh: consulting fees: Alcon Laboratories, Genentech, Regeneron, Allergan, ThromboGenics, Shire; contract research: Genentech, Regeneron, ThromboGenics.